<DOC>
	<DOCNO>NCT00391638</DOCNO>
	<brief_summary>HBe seroconversion important goal anti-HBV treatment , since associate non progressive liver infection well clinical outcome . However , rate HBe seroconversion low HIV-HBV co-infected patient , mostly treat tenofovir emtricitabine . This study evaluate efficacy safety one-year Peg-interferon alpha 2a additional treatment patient already treat tenofovir emtricitabine without reach HBe seroconversion .</brief_summary>
	<brief_title>Efficacy Tolerance Peg-interferon Alpha 2a Added Tenofovir Emtricitabine AgHBe Positive HBV-HIV Co-infected Patients</brief_title>
	<detailed_description>Many HBV-HIV co-infected patient currently treat dual activity drug tenofovir emtricitabine , often combination . However , despite potent antiviral activity drug , rate HBe seroconversion quite low , always sustain time . HBe seroconversion important goal anti-HBV treatment , since associate non progressive liver infection well clinical outcome . On hand , treatment antiviral immuno-modulator activity Peg-interferon , infrequently use co-infected patient , despite promising data field HBV mono-infection increase rate sustain HBe seroconversions . This pilot study evaluate efficacy safety one-year Peg-interferon alpha 2a additional treatment ( 180 micro-g week , injection ) , 55 patient already treat tenofovir emtricitabine least 6 month , reach HBe seroconversion</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>HIV infection Karnofsky 80 per cent Stable ARV since 4 month CD4 200 per mm3 ARN VIH 10000 copy per ml hepatitis B chronic : positive antigenaemia HBe negative antiHBe , positive DNA HBV tenofovir treatment , DNA HBV negative 10000 copy per ml W8 . Previous treatment tenofovir lamivudine emtricitabine 6 month HIV 2 infection Hepatitis C D Opportunistic infection Alcool consummation 50g/d Cirrhosis Pregnancy plan pregnancy Breastfeeding Immunosuppressive modulate immune response treatment Other Hepatitis B treatment tenofovir , lamivudine emtricitabine since 6 month Malabsorption Exclusive HIV therapy Truvada Evolutive cancer chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>HIV Hepatitis B coinfection</keyword>
	<keyword>Peg interferon</keyword>
	<keyword>tenofovir</keyword>
	<keyword>emtricitabine</keyword>
	<keyword>Hepatitis B e Antigens</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>